rs588765 — CHRNA5 5' UTR / Locus 3

The Expression Dial: How CHRNA5 mRNA Levels Shape Nicotine Addiction Risk

The CHRNA5 gene on chromosome 15q25.1 encodes the alpha-5 subunit of the neuronal nicotinic acetylcholine receptor — a critical component of the brain circuits that govern how aversive nicotine feels at high doses. Most research on this region has focused on rs16969968, an amino acid change (Asp398Asn) that blunts receptor function. But there is a second, molecularly distinct mechanism at work: variation in how much CHRNA5 is made¹¹ variation in how much CHRNA5 is made
rs588765 tags a cis-regulatory haplotype that controls CHRNA5 transcription in brain and lung, independent of any protein-coding change. rs588765 is the tag SNP for this second locus (Locus 3, or Bin B), and it operates entirely through gene expression quantity rather than protein quality.

The T allele at rs588765 is associated with approximately 4.7-fold higher CHRNA5 mRNA levels compared to CC homozygotes — a large expression difference for a common variant. Because more alpha-5 subunit is available, more functional α4β2α5 receptors assemble in key brain regions including the medial habenula and interpeduncular nucleus. This in turn affects the sensitivity of the aversive-response pathway to nicotine. When the non-risk amino acid variant (GG at rs16969968) co-occurs with high expression (TT at rs588765)²² When the non-risk amino acid variant (GG at rs16969968) co-occurs with high expression (TT at rs588765)
The GG_TT diplotype shows OR=1.72 for nicotine dependence in European American brain tissue samples — a substantial risk elevation from gene expression alone, independent of the coding change, the risk for nicotine dependence is substantially elevated.

The Mechanism

The medial habenula–interpeduncular nucleus (MHb–IPN) axis is sometimes called the brain's "nicotine brake": high nicotine concentrations activate α4β2α5 receptors in this pathway, generating aversive signals (discomfort, nausea) that normally cap smoking. When alpha-5 subunit expression is high (T allele), more receptor complexes are assembled in this pathway, and the brake becomes more tightly coupled to nicotine concentration — paradoxically increasing sensitivity in ways that facilitate dependence at lower-dose exposure thresholds. When expression is low (C allele), fewer receptors are available and the circuit operates differently.

The rs588765 intronic region appears to contain regulatory elements that control CHRNA5 transcription. Conditional analysis in cis-regulatory variant studies³³ Conditional analysis in cis-regulatory variant studies
rs3841324 and rs880395 — variants in the 2.5 kb upstream region — explain most of the expression signal, with rs588765 acting as a proxy tag in high LD with these functional elements in Europeans suggests the true causal regulatory element lies in a 2.5 kb region upstream of CHRNA5, with rs588765 serving as a high-LD proxy (r²=0.88 with rs3841324 in Europeans). The expression effect replicates in both European American and African American prefrontal cortex, and has been confirmed in lung tissue by GTEx, making this a biologically robust eQTL.

The Evidence

The key Wang et al. 2009 study⁴⁴ Wang et al. 2009 study
Analyzed CHRNA5 mRNA expression from 94 European American brain samples alongside nicotine dependence case-control data; diplotype analysis revealed independent effects of coding vs. expression variants demonstrated that the GG_TT diplotype (non-risk coding variant + high expression) confers OR=1.72 (95% CI 1.19–2.47) for nicotine dependence compared to GG_CC (non-risk coding + low expression). This established that expression level and amino acid change are two distinct, additive mechanisms at 15q25.1.

The independent GWAS signal at this locus was first confirmed at genome-wide significance by Thorgeirsson et al. 2010⁵⁵ Thorgeirsson et al. 2010
Meta-analysis including >30,000 individuals; rs588765 was associated only in conditional analyses after adjustment for rs16969968, who showed that after conditioning on rs16969968, rs588765 achieves p=8.7×10⁻⁸ with OR=1.27 (95% CI 1.16–1.38) for heavy versus light smoking. This conditionality confirms that rs588765 is not simply tagging the rs16969968 haplotype, but represents an independent biological signal that only becomes visible when the dominant coding-variant effect is removed from the analysis.

In COPD patients, a genome-wide association study of smoking behaviors⁶⁶ a genome-wide association study of smoking behaviors
Genome-wide scan in COPD patients from the ECLIPSE cohort found rs588765 nominally associated with lifetime average cigarettes per day (p=0.046), consistent with prior GWAS direction found that rs588765 and rs578776 represent independent haplotypes associated with lifetime average cigarettes per day, with consistent directional effects. In lung cancer risk specifically, a meta-analysis of CHRNA variants⁷⁷ meta-analysis of CHRNA variants
Epidemiological meta-analysis assigned strong evidence to rs588765 for lung cancer risk under the recessive model in Caucasians (OR=1.19, p<0.001) and moderate evidence for other genetic models assigned strong evidence to rs588765 under the recessive model in Caucasian populations (OR=1.19, 95% CI 1.11–1.28).

The expression effect is population-consistent. Cross-ancestry replication⁸⁸ Cross-ancestry replication
Expression QTL analysis in both European and African American prefrontal cortex showed significant association with T allele at rs588765 in both groups; African p=1.10×10⁻⁴, European p=3.11×10⁻¹⁰ confirmed the T allele increases CHRNA5 expression in African Americans (p=1.10×10⁻⁴) as well as Europeans (p=3.11×10⁻¹⁰), though the LD structure and proxy relationships differ somewhat by ancestry.

Practical Actions

The independent expression-level signal at rs588765 adds information beyond what rs16969968 captures. Carrying the TT genotype at rs588765 on a GG background at rs16969968 means your risk for nicotine dependence is elevated through the expression pathway even without the coding-change risk. The two loci have additive effects: a person carrying both the rs16969968 AA genotype and the rs588765 TT genotype has the highest combined burden at this cluster.

For never-smokers, TT homozygotes should be aware that their elevated CHRNA5 expression may confer added vulnerability to nicotine dependence if they initiate tobacco use. For current smokers carrying TT, standard cessation pharmacotherapy (varenicline or bupropion) that works independently of CHRNA5 expression levels is the preferred approach, as the expression-level effect cannot be directly modified. The lung cancer signal at this locus provides additional motivation for earlier screening discussions in individuals with substantial smoking history.

Interactions

rs588765 is in low linkage disequilibrium with rs16969968 (the coding D398N variant), meaning the two provide independent genetic risk information. The critical biological insight is haplotype-level: the highest-risk diplotype is AA_TT — homozygous for both the function-reducing coding change at rs16969968 AND the high-expression allele at rs588765. The GG_CC diplotype (non-risk coding + low expression) appears to be the most protective combination.

In terms of proxy relationships, rs588765 is in high LD with rs880395 (r²≈0.88 in Europeans), which several analyses identify as a more proximal regulatory variant. GeneOps includes both independently because they behave differently in non-European populations where LD patterns diverge. The third independent locus at 15q25.1 is rs578776 (Locus 2, associated with reward sensitivity), which is distinct from rs588765 in both mechanism and genomic position.